Plain-English translation of NCT07454187 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new medication called given by injection to treat multiple myeloma—a cancer of blood cells—specifically in patients whose disease has come back or stopped responding to prior treatments. The main goal is to find out if the medication is safe and tolerable, and to see how well it works against the cancer. Researchers will also study how the medication moves through your body and how it affects your immune system.
Multiple myeloma can become resistant to standard treatments, leaving patients with limited options. This trial exists to see if this new medication offers another effective choice for people whose cancer has stopped responding to earlier therapies.
You likely qualify if…
You likely don't qualify if…
You will receive by injection as your only cancer treatment in this study. The trial uses a dose-escalation design, meaning early participants receive lower doses while researchers monitor safety before gradually increasing doses for later participants. You will have regular visits to the clinic for blood tests, physical exams, and disease assessments to track how well the medication is working and to watch for any side effects. The study involves about 40 patients total and is being conducted at multiple centers in China.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China